UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer's Disease

International journal of molecular sciences, 2023-06, Vol.24 (13), p.10523

2023

Volltextzugriff (PDF)

Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity

PLoS pathogens, 2017-11, Vol.13 (11), p.e1006733

2017

Volltextzugriff (PDF)

Development of mavoglurant and its potential for the treatment of fragile X syndrome

Expert opinion on investigational drugs, 2014-01, Vol.23 (1), p.125-134

2014

Volltextzugriff (PDF)

Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

British journal of pharmacology, 2001-04, Vol.132 (7), p.1423-1430

2001

Volltextzugriff (PDF)

Novel allosteric antagonists shed light on mglu5 receptors and CNS disorders

Trends in pharmacological sciences (Regular ed.), 2001-07, Vol.22 (7), p.331-337

2001

Volltextzugriff (PDF)

Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents

The Journal of pharmacology and experimental therapeutics, 2000-12, Vol.295 (3), p.1267

2000

Volltextzugriff (PDF)

The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors

The Journal of biological chemistry, 2000-10, Vol.275 (43), p.33750-33758

2000

Volltextzugriff (PDF)

CPCCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding

Molecular pharmacology, 1999-03, Vol.55 (3), p.453

1999

Volltextzugriff (PDF)

ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: Identification, in vitro pharmacology, pharmacokinetic and biodistribution studies

Bioorganic & medicinal chemistry, 2007-01, Vol.15 (2), p.903-914

2007

Volltextzugriff (PDF)

Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome

Clinical epigenetics, 2016-02, Vol.8 (15), p.15-15, Article 15

2016

Volltextzugriff (PDF)

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

BMC medical genetics, 2012-03, Vol.13 (1), p.13-13, Article 13

2012

Volltextzugriff (PDF)

Effects of the prototypical mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats

European journal of pharmacology, 2000-10, Vol.406 (3), p.403-410

2000

Volltextzugriff (PDF)

Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists

ChemMedChem, 2010-10, Vol.5 (10), p.1693-1696

2010

Volltextzugriff (PDF)

VHB937, a TREM2 Stabilizing and Activating Antibody Strongly Reduces Pathology After Peripheral Administration in a Broad Range of Animal Models for Neuroinflammation and Neurodegeneration (P4-4.004)

Neurology, 2024-04, Vol.102 (17_supplement_1)

2024

Volltextzugriff (PDF)

SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5

The Journal of pharmacology and experimental therapeutics, 1999-07, Vol.290 (1), p.170

1999

Volltextzugriff (PDF)

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Nature reviews. Drug discovery, 2018-04, Vol.17 (4), p.280-299

2018

Volltextzugriff (PDF)

Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers

European journal of nuclear medicine and molecular imaging, 2008-04, Vol.35 (4), p.766-770

2008

Volltextzugriff (PDF)

THE CMS MUON DETECTOR: FROM THE FIRST THOUGHTS TO THE FINAL DESIGN

International journal of modern physics. A, Particles and fields, gravitation, cosmology, 2010-06, Vol.25 (16), p.3121-3154

GASPARINI, FABRIZIO

2010

Volltextzugriff (PDF)

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056

Science translational medicine, 2011-01, Vol.3 (64), p.64ra1

2011

Volltextzugriff (PDF)

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome

Human molecular genetics, 2018-06, Vol.27 (12), p.2039-2051

2018

Volltextzugriff (PDF)

Sustained Trem2 stabilization accelerates microglia heterogeneity and Aβ pathology in a mouse model of Alzheimer’s disease

Cell reports (Cambridge), 2022-05, Vol.39 (9), p.110883-110883, Article 110883

2022

Volltextzugriff (PDF)

AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: Identification, SAR and pharmacological characterization

Bioorganic & medicinal chemistry, 2014-11, Vol.22 (21), p.5790-5803

2014

Volltextzugriff (PDF)

Translating molecular advances in fragile X syndrome into therapy: a review

The journal of clinical psychiatry, 2014-04, Vol.75 (4), p.e294-e307

2014

Volltextzugriff (PDF)

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome

Human molecular genetics, 2018-11, Vol.27 (21), p.3825-3825

2018

Volltextzugriff (PDF)

Quantitative evaluation of 11C-ABP688 as PET ligand for the measurement of the metabotropic glutamate receptor subtype 5 using autoradiographic studies and a beta-scintillator

NeuroImage (Orlando, Fla.), 2007-04, Vol.35 (3), p.1086-1092

2007

Volltextzugriff (PDF)

1 – 25 von 156

Suche als RSS-Feed

Aktive Filter

ThemaNeurosciences & Neurology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(141)
Mit Volltextzugriff
(127)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(102)
Life Sciences & Biomedicine
(92)
Humans
(79)
Male
(56)
Female
(44)
Animals
(32)
Middle Aged
(27)
Biological And Medical Sciences
(26)
Medical Sciences
(25)
Pharmacology & Pharmacy
(25)
Aged
(24)
Adult
(21)
Receptors, Metabotropic Glutamate - Antagonists & Inhibitors
(20)
Oncology
(18)
Pharmacology. Drug Treatments
(17)
Cardiac & Cardiovascular Systems
(16)
Cardiovascular System & Cardiology
(16)
Adolescent
(14)
Child
(14)
Neuropharmacology
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Central and Peripheral Inflammation in Mild Cognitive Impairment in the Context of Alzheimer's Disease

Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity

Development of mavoglurant and its potential for the treatment of fragile X syndrome

Potential anxiolytic‐ and antidepressant‐like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

Novel allosteric antagonists shed light on mglu5 receptors and CNS disorders

Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents

The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors

CPCCOEt, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signaling Without Affecting Glutamate Binding

ABP688, a novel selective and high affinity ligand for the labeling of mGlu5 receptors: Identification, in vitro pharmacology, pharmacokinetic and biodistribution studies

Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro

Effects of the prototypical mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats

Design and Synthesis of Selective and Potent Orally Active S1P5 Agonists

VHB937, a TREM2 Stabilizing and Activating Antibody Strongly Reduces Pathology After Peripheral Administration in a Broad Range of Animal Models for Neuroinflammation and Neurodegeneration (P4-4.004)

SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers

THE CMS MUON DETECTOR: FROM THE FIRST THOUGHTS TO THE FINAL DESIGN

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome

Sustained Trem2 stabilization accelerates microglia heterogeneity and Aβ pathology in a mouse model of Alzheimer’s disease

AFQ056/mavoglurant, a novel clinically effective mGluR5 antagonist: Identification, SAR and pharmacological characterization

Translating molecular advances in fragile X syndrome into therapy: a review

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome

Quantitative evaluation of 11C-ABP688 as PET ligand for the measurement of the metabotropic glutamate receptor subtype 5 using autoradiographic studies and a beta-scintillator

Aktive Filter

Suchergebnisse filtern